Read More

Nutrien To Highlight Strategic Priorities And 2026 Targets At Investor Day Today At 10:00 a.m. ET; Targeting Retail Adjusted EBITDA Of $1.9B-$2.1B In 2026, Including A Goal Of $1.4B In Gross Margin From Proprietary Products Portfolio; Intends To Reduce…

Strategic Priorities and Performance TargetsSimplifying portfolio and focusing on core assets and markets to enhance earnings quality and free cash flow.Prioritizing investments to enhance our North American fertilizer


Read More

Genmab, BioNTech Announced Data At ASCO, Showing Investigational Acasunlimab In Combination With Pembrolizumab Resulted In 12-month Overall Survival Rate of 69% In Patients With Previously Treated Metastatic Non-small Cell Lung Cancer

Genmab A/S (NASDAQ:GMAB) and BioNTech SE (NASDAQ:BNTX) todayannounced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating acasunlimab (DuoBody-PD-L1x4-1BB), an investigational bispecific antibody also